Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

ePoster Display

148P - Phase III study of everolimus or placebo in addition to adjuvant hormone therapy for high risk early breast cancer: Subgroup analysis of the UCBG UNIRAD trial

Date

16 Sep 2021

Session

ePoster Display

Topics

Cytotoxic Therapy;  Clinical Research

Tumour Site

Breast Cancer

Presenters

Paul Cottu

Citation

Annals of Oncology (2021) 32 (suppl_5): S407-S446. 10.1016/annonc/annonc687

Authors

P.H. Cottu1, F. Dalenc2, S. Chabaud3, D. Allouache4, D. Cameron5, J. Jacquin6, J. Grenier7, P. Barthelemy8, M. Brunt9, L. Kaluzinski10, A. Mailliez11, E. Legouffe12, A. Hardy-Bessard13, S. Giacchetti14, M.A. Mouret Reynier15, J. Canon16, J. Bliss17, J. Lemonnier18, F. André19, T. Bachelot20

Author affiliations

  • 1 Medical Oncology, Institut Curie, 75005 - Paris/FR
  • 2 Medical Oncology, IUCT Centre Claudius-Regaud, 31052 - Toulouse/FR
  • 3 Biostatistics And Therapeutics Evaluation Unit, Centre Léon Bérard, 69373 - Lyon/FR
  • 4 Medical Oncology, Centre Francois Baclesse, 14076 - Caen/FR
  • 5 Medical Oncology, Edinburgh Cancer Centre Western General Hospital, EH4 2XU - Edinburgh/GB
  • 6 Medical Oncology, Institut de Cancérologie de la Loire (ICO), 42271 - Saint Priest en Jarez/FR
  • 7 Medical Oncology, Institut Ste Catherine, 84082 - Avignon/FR
  • 8 Medical Oncology, ICANS - Institut de Cancérologie Strasbourg Europe, 67200 - Strasbourg/FR
  • 9 Medical Oncology Department, Royal Stoke University Hospital, ST4 6QG - Stoke-On-Trent/GB
  • 10 Medical Oncology, Hospital de Cherbourg, 50102 - Cherbourg-Octeville/FR
  • 11 Medical Oncology, Centre Oscar Lambret, 59020 - Lille/FR
  • 12 Medical Oncology, Institut de Cancérologie du Gard, 30029 - Nimes/FR
  • 13 Medical Oncology, Centre CARIO HPCA, 22190 - Plérin/FR
  • 14 Medical Oncology, Hôpital Saint Louis, 75475 - Paris/FR
  • 15 Medical Oncology, Centre Jean Perrin, 63011 - Clermont-Ferrand/FR
  • 16 Department Of Oncology-hematology, Grand Hopital de Charleroi Site Notre Dame, 6000 - Charleroi/BE
  • 17 Clinical Trials And Statistics Unit, ICR - Institute of Cancer Research, SW7 3RP - London/GB
  • 18 Research And Development, UNICANCER, 75654 - Paris/FR
  • 19 Breast Cancer Unit, Medical Oncology Department, Gustave Roussy - Cancer Campus, 94805 - Villejuif/FR
  • 20 Medical Oncology Department, Centre Léon Bérard, 69008 - Lyon/FR

Resources

Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

Abstract 148P

Background

The double blind randomized UNIRAD trial (NCT01805271) showed that adding Everolimus (EVE) to adjuvant endocrine therapy (ET) for high-risk early breast cancer (BC) does not improve 3-year disease-free survival (iDFS) compared with ET alone. We report the subgroup analysis focusing on the pre-specified stratification factors.

Methods

Women with high-risk HR+/HER2- early BC who had completed initial treatment and started adjuvant ET were randomly allocated (1:1) to placebo (Pbo) or EVE for 2 years. Primary endpoint was iDFS from randomization. ET treatment was investigator’s choice. Pre-specified stratification factors included ET treatment: tamoxifen (TAM) or aromatase inhibitor (AI); adjuvant or neo-adjuvant chemotherapy; progesterone receptor (PR) status; duration of adjuvant ET before inclusion (≤3 Years/>3 years); inclusion based on tumor stage (≥4 N+ or ≥ 1N+ after neoadjuvant treatment) or on the Endopredict test ® (≥ 1N+ and EPclin score ≥ 3.3).

Results

1278 pts were randomized between June 2013 and March 2020; 641 in the Pbo arm, and 637 in the EVE arm. 773 (60.4%) and 505 (39.4%) received AI or TAM as adjuvant ET, respectively. After a median follow up of 35.7 months, 3 years iDFS rate (iDFS-3y) was 88% in both arms (HR=0.95; 95%CI: 0.69-1.32). The only significant interaction between stratification factors and treatment group was ET backbone (p= 0.044). In TAM treated patients, iDFS-3y was 91% and 86% in the EVE and Pbo arms, respectively (HR=0.63; 95%CI: 0.369-1.05). In AI treated patients, iDFS-3y was 87% and 91% in the EVE and Pbo arms, respectively (HR=1.25; 95%CI: 0.82-1.9). Proportion of dose reduction was similar in TAM and AI patients, but early treatment discontinuation was less frequent in TAM than in AI patients: 48.0% vs 56.9%, respectively (p=0.028). Accordingly, median duration of EVE exposition was 12.8 months when combined with TAM and only 7.7 months when combined with an AI (p=0.007).

Conclusions

This subgroup analysis suggest that in patients with high risk early HR+/HER2- BC adjuvant EVE may be associated with different tolerability and therapeutic effect when combined with TAM or AI. Interaction with age or menopausal status is worth exploring.

Clinical trial identification

NCT01805271.

Editorial acknowledgement

Legal entity responsible for the study

UNICANCER.

Funding

Novartis, Myriad Genetics, French Ministry of Health (PHRC 2012).

Disclosure

P.H. Cottu: Financial Interests, Personal and Institutional, Advisory Role: Pfizer; Financial Interests, Personal and Institutional, Advisory Role: Lilly; Financial Interests, Institutional, Advisory Role: Roche Genentech; Financial Interests, Institutional, Research Grant: Pfizer; Financial Interests, Institutional, Research Grant: Novartis; Non-Financial Interests, Personal, Other, Travel: Roche; Non-Financial Interests, Personal, Other, Travel: Pfizer; Financial Interests, Institutional, Advisory Role: NanoString Tech; Financial Interests, Personal, Advisory Role: Roche; Financial Interests, Personal, Advisory Role: Pierre Fabre; Financial Interests, Institutional, Advisory Role: Novartis. F. Dalenc: Financial Interests, Institutional, Advisory Role: Novartis; Financial Interests, Institutional, Advisory Role: Roche; Financial Interests, Institutional, Advisory Role: AstraZeneca; Financial Interests, Institutional, Advisory Role: Pfizer; Financial Interests, Institutional, Advisory Role: MSD; Financial Interests, Institutional, Advisory Role: Pierre Fabre; Non-Financial Interests, Personal, Other, Travel accommodation: Roche; Non-Financial Interests, Personal, Other, Travel accommodation: Pfizer; Non-Financial Interests, Personal, Other, Travel accommodation: Novartis; Non-Financial Interests, Personal, Other, Travel accommodation: Amgen. D. Cameron: Financial Interests, Institutional, Advisory Role: Novartis; Financial Interests, Institutional, Advisory Role: Pfizer; Financial Interests, Institutional, Advisory Role: Lilly. A. Hardy-Bessard: Financial Interests, Personal and Institutional, Advisory Role: Novartis; Financial Interests, Personal and Institutional, Advisory Role: Pfizer; Financial Interests, Personal and Institutional, Advisory Role: AstraZeneca; Financial Interests, Personal and Institutional, Advisory Role: MSD; Financial Interests, Personal and Institutional, Advisory Role: Clovis; Non-Financial Interests, Institutional, Other, Travel: Roche. S. Giacchetti: Financial Interests, Personal and Institutional, Advisory Role: Pfizer; Financial Interests, Personal and Institutional, Advisory Role: Novartis. J. Bliss: Financial Interests, Institutional, Advisory Role: Novartis; Financial Interests, Institutional, Advisory Role: AstraZeneca; Financial Interests, Institutional, Advisory Role: Clovis Oncology; Financial Interests, Institutional, Advisory Role: Janssen Cilag; Financial Interests, Institutional, Advisory Role: Merck; Financial Interests, Institutional, Advisory Role: Puma Biotech; Financial Interests, Institutional, Advisory Role: Pfizer; Financial Interests, Institutional, Advisory Role: Medivation; Financial Interests, Institutional, Advisory Role: Eli Lilly. F. André: Financial Interests, Personal and Institutional, Advisory Role: Pfizer; Non-Financial Interests, Personal, Other, Travel: Pfizer; Financial Interests, Institutional, Research Grant: Pfizer; Non-Financial Interests, Personal, Other, Travel: Roche; Financial Interests, Institutional, Research Grant: Roche; Financial Interests, Personal and Institutional, Advisory Role: Roche; Financial Interests, Personal and Institutional, Advisory Role: Lilly; Financial Interests, Institutional, Research Grant: Novartis; Financial Interests, Institutional, Research Grant: Genentech; Financial Interests, Institutional, Advisory Role: NanoString Technologies. T. Bachelot: Non-Financial Interests, Personal, Other, Travel: Roche; Non-Financial Interests, Personal, Other, Travel: Novartis; Non-Financial Interests, Personal, Other, Travel: AstraZeneca; Non-Financial Interests, Personal, Other, Travel: Pfizer; Financial Interests, Institutional, Research Grant: Pfizer; Financial Interests, Institutional, Research Grant: Novartis; Financial Interests, Personal and Institutional, Advisory Role: Pfizer; Financial Interests, Personal and Institutional, Advisory Role: Roche; Financial Interests, Personal and Institutional, Advisory Role: Genentech; Financial Interests, Personal and Institutional, Advisory Role: Lilly. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.